Xconomy
DECEMBER 14, 2018
Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used insulin. The patent holder, the University of Toronto, gave companies the right to manufacture insulin. to offer competitive pricing pressure. to offer competitive pricing pressure.
Xconomy
JULY 24, 2020
EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices than existing medicines. But it offered few specifics about how it would achieve those goals.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TechCrunch LA
MARCH 22, 2018
Our research revealed a saturation level causing unprecedented challenges, starting with exorbitant housing prices and runaway operating costs that accelerate a startup’s “burn rate”—its monthly spending. Suster has also noted for years that the region produces more technology doctorates than any other geography in the United States.
Xconomy
SEPTEMBER 6, 2019
Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something better. is counting on.
Xconomy
JULY 26, 2019
What will the legacy be of Jeff Leiden, the longtime CEO of Vertex Pharmaceuticals? Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written. He steered Vertex through a crisis when its hepatitis C business was squashed by competition.
Xconomy
JUNE 3, 2016
Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin). billion acquisition of San Diego’s Auspex Pharmaceuticals last year.
Xconomy
FEBRUARY 10, 2017
All this, plus heart-stopping patent fights, drug-price intrigue, a regenerative chat with inventor Dean Kamen, and more. Let’s get to the roundup. BAN IN THE U.S.A. —A federal appeals court upheld a freeze of the Trump administration’s temporary ban on travelers from seven Muslim-majority countries.
Expert insights. Personalized for you.
77 
Let's personalize your content